Wednesday, July 8, 2026

Patent intelligence · US

US 11673887

N-acyl amino acid compounds and methods of use

granted A61PA61P1/00A61P1/16A61P11/00
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 17
Applicant portfolio 13
Patent details — US 11673887
Jurisdiction
US
Status
granted
Grant date
Jun 13, 2023
Expiration
Jun 8, 2043
Claims
68
CPC classes
A61P, A61P1/00, A61P1/16, A61P11/00
View on Google Patents ↗

Quick answer

US 11673887 (N-acyl amino acid compounds and methods of use) is held by Pliant Therapeutics, Inc.. Status: granted. Granted Jun 13, 2023. Expires Jun 8, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
68
CPC classes
A61P, A61P1/00, A61P1/16, A61P11/00, A61P13/12, A61P17/00

More from Pliant Therapeutics, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12390463

    Dosage forms and regimens for amino acid compounds

    Pliant Therapeutics, Inc. · Expires Aug 14, 2045

    granted
  2. US 12134642

    Antibodies binding to α7β1 integrin antibodies and compositions thereof

    Pliant Therapeutics, Inc. · Expires Oct 31, 2044

    granted
  3. US 11952376

    Substituted amino acids as integrin inhibitors

    Pliant Therapeutics, Inc. · Expires Apr 4, 2044

    granted
  4. US 11858931

    Amino acid compounds with unbranched linkers and methods of use

    Pliant Therapeutics, Inc. · Expires Dec 28, 2043

    granted
  5. US 11634418

    Amino acid compounds and methods of use

    Pliant Therapeutics, Inc. · Expires Apr 20, 2043

    granted
  6. US 11560376

    Amino acid compounds and methods of use

    Pliant Therapeutics, Inc. · Expires Jan 19, 2043

    granted
  7. US 11419869

    Dosage forms and regimens for amino acid compounds

    Pliant Therapeutics, Inc. · Expires Aug 18, 2042

    granted

Frequently asked questions

What is US patent 11673887?

US 11673887 (N-acyl amino acid compounds and methods of use) is held by Pliant Therapeutics, Inc.. Status: granted. Granted Jun 13, 2023. Expires Jun 8, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11673887?

Pliant Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 13 pharmaceutical patents for this assignee.

When does US 11673887 expire?

Our index shows an expiration date of Jun 8, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.